利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

10 条记录 (耗时 0.028 秒)

    SELECTIVE MODULATION OF RENAL NERVES
    1.
    发明申请
    SELECTIVE MODULATION OF RENAL NERVES 审中-公开
    选择性调节肾脏神经

    公开(公告)号：US20150133850A1

    公开(公告)日：2015-05-14

    申请号：US14379834

    申请日：2013-03-07

    申请人： Stefan TUNEV ,  MEDTRONIC ARDIAN LUXEMBOURG SARL

    发明人： Stefan Tunev ,  Julie Trudel

    IPC分类号： A61B18/04 ,  A61B18/02 ,  A61N1/32 ,  A61M25/00 ,  A61N7/00 ,  A61B18/14 ,  A61B18/18

    CPC分类号： A61B18/04 ,  A61B18/02 ,  A61B18/1492 ,  A61B18/1815 ,  A61B2018/00434 ,  A61B2018/046 ,  A61M25/0084 ,  A61M2025/0089 ,  A61M2202/048 ,  A61M2202/049 ,  A61N1/0551 ,  A61N1/327 ,  A61N1/3605 ,  A61N7/00 ,  A61N2007/003

    摘要： Methods for treating a patient using therapeutic renal neuromodulation and associated devices, systems, and methods are disclosed herein. One aspect of the present technology is directed to methods including selectively neuromodulating afferent or efferent renal nerves. One or more measurable physiological parameters corresponding to systemic sympathetic overactivity or hyperactivity in the patient can thereby be reduced. Selectively neuromodulating afferent renal nerves can include inhibiting sympathetic neural activity in nerves proximate a renal pelvis. This can include, for example, neuromodulating via fluid within the renal pelvis. Selectively neuromodulating efferent renal nerves can include inhibiting sympathetic neural activity in nerves proximate a portion of a renal artery or a renal branch artery proximate a renal parenchyma. This can include, for example, neuromodulating via a therapeutic element within the portion of the renal artery or the renal branch artery.

    摘要翻译： 本文公开了使用治疗性肾神经调节和相关联的装置，系统和方法治疗患者的方法。 本技术的一个方面涉及包括选择性神经调节传入或传出肾神经的方法。 因此可以减少对应于患者的全身交感神经过度活动或多动症的一个或多个可测量的生理参数。 选择性神经调节传入肾神经可以包括抑制邻近肾盂的神经中的交感神经活动。 这可以包括例如通过肾盂内的流体进行神经调节。 选择性神经调节传出肾神经可以包括抑制邻近肾动脉的一部分或靠近肾实质的肾分支动脉的神经中的交感神经活动。 这可以包括例如通过肾动脉或肾分支动脉部分内的治疗元件神经调节。

    Selective modulation of renal nerves
    2.
    发明授权
    Selective modulation of renal nerves 有权

    公开(公告)号：US10342592B2

    公开(公告)日：2019-07-09

    申请号：US14379834

    申请日：2013-03-07

    申请人： MEDTRONIC ARDIAN LUXEMBOURG SARL ,  Stefan Tunev

    发明人： Stefan Tunev ,  Julie Trudel

    IPC分类号： A61B18/00 ,  A61B18/04 ,  A61N1/05 ,  A61N1/36 ,  A61B18/02 ,  A61B18/14 ,  A61B18/18 ,  A61M25/00 ,  A61N1/32 ,  A61N7/00

    摘要： Methods for treating a patient using therapeutic renal neuromodulation and associated devices, systems, and methods are disclosed herein. One aspect of the present technology is directed to methods including selectively neuromodulating afferent or efferent renal nerves. One or more measurable physiological parameters corresponding to systemic sympathetic overactivity or hyperactivity in the patient can thereby be reduced. Selectively neuromodulating afferent renal nerves can include inhibiting sympathetic neural activity in nerves proximate a renal pelvis. This can include, for example, neuromodulating via fluid within the renal pelvis. Selectively neuromodulating efferent renal nerves can include inhibiting sympathetic neural activity in nerves proximate a portion of a renal artery or a renal branch artery proximate a renal parenchyma. This can include, for example, neuromodulating via a therapeutic element within the portion of the renal artery or the renal branch artery.

    SELECTIVE MODULATION OF RENAL NERVES
    6.
    发明申请
    SELECTIVE MODULATION OF RENAL NERVES 有权

    公开(公告)号：US20230024234A1

    公开(公告)日：2023-01-26

    申请号：US17937289

    申请日：2022-09-30

    申请人： Stefan Tunev ,  Julie Trudel

    发明人： Stefan Tunev ,  Julie Trudel

    IPC分类号： A61B18/04 ,  A61N1/05 ,  A61N1/36 ,  A61B18/02 ,  A61B18/14 ,  A61B18/18 ,  A61M25/00 ,  A61N1/32 ,  A61N7/00

    摘要： Methods for treating a patient using therapeutic renal neuromodulation and associated devices, systems, and methods are disclosed herein. One aspect of the present technology is directed. to methods including selectively neuromodulating afferent or efferent renal nerves, One or more measurable physiological parameters corresponding to systemic sympathetic overactivity or hyperactivity in the patient can thereby be reduced. Selectively neuromodulating afferent renal nerves can include inhibiting sympathetic neural activity in nerves proximate a renal pelvis. This can include, for example, neuromodulating via fluid within the renal pelvis. Selectively neuromodulating efferent renal nerves can include inhibiting sympathetic neural activity in nerves proximate a portion of a renal artery or a renal branch artery proximate a renal parenchyma. This can include, for example, neuromodulating via a therapeutic element within the portion of the renal artery or the renal branch artery.

    Large Animal Model for Human-Like Advanced Atherosclerotic Plaque
    7.
    发明申请
    Large Animal Model for Human-Like Advanced Atherosclerotic Plaque 审中-公开
    人类先进动脉粥样硬化斑块的大动物模型

    公开(公告)号：US20100124533A1

    公开(公告)日：2010-05-20

    申请号：US12274817

    申请日：2008-11-20

    申请人： Stefan Tunev ,  Ankit Shah ,  Alejandra Caceres ,  Ya Guo ,  Julie Trudel ,  Phean Him ,  Ayala Hezi-Yamit

    发明人： Stefan Tunev ,  Ankit Shah ,  Alejandra Caceres ,  Ya Guo ,  Julie Trudel ,  Phean Him ,  Ayala Hezi-Yamit

    IPC分类号： A61B10/00 ,  A01K67/00

    CPC分类号： A01K67/027 ,  A01K2217/00 ,  A01K2227/108 ,  A01K2267/03 ,  A01K2267/0375

    摘要： An animal model for cardiovascular disease comprising one or more vascular plaque lesions formed at selected sites within a vascular segment of a nonhuman mammal. The vascular plaque lesion is formed by administering a hypercholesterolemic diet to the nonhuman mammal, inflicting an injury to the vascular wall at the selected site after a predetermined exposure to the hypercholesterolemic diet, and applying a hydrogel to the injured vascular wall. Another aspect of the invention provides a method for evaluating a test compound for an effect on atherosclerotic lesion formation comprising administering to a nonhuman mammal a hypercholesterolemic diet, and, after a defined period of time, isolating a segment of a blood vessel using a balloon catheter, inflicting an injury to the vascular wall within the isolated segment, and applying a hydrogel within the vascular segment. The method further comprises forming a vascular plaque lesion on the vascular wall at the site of the injury, delivering the test compound to the nonhuman mammal, and monitoring atherosclerotic lesion size and composition at the injured site after a defined period of exposure to the test compound.

    摘要翻译： 一种用于心血管疾病的动物模型，其包含在非人哺乳动物的血管片段内的选定位置处形成的一个或多个血管斑块损伤。 通过向非人哺乳动物施用高胆固醇血症饮食来形成血管斑块损伤，在预先暴露于高胆固醇血症饮食之后对选定部位的血管壁施加损伤，并将水凝胶施加到损伤的血管壁。 本发明的另一方面提供了一种用于评估对动脉粥样硬化病变形成的影响的测试化合物的方法，包括向非人类哺乳动物施用高胆固醇血症饮食，并且在限定的时间段之后，使用气囊导管分离血管的一段 对隔离区段内的血管壁造成损伤，并在血管段内施用水凝胶。 该方法还包括在损伤部位的血管壁上形成血管斑块损伤，将测试化合物递送至非人类哺乳动物，并在暴露于测试化合物的确定的时间段后监测受伤部位的动脉粥样硬化病变大小和组成 。

    Apparatus and Methods for Recanalization of a Chronic Total Occlusion
    10.
    发明申请
    Apparatus and Methods for Recanalization of a Chronic Total Occlusion 审中-公开
    慢性全部闭塞再通的装置和方法

    公开(公告)号：US20120259314A1

    公开(公告)日：2012-10-11

    申请号：US13083764

    申请日：2011-04-11

    申请人： Ya Guo ,  Stefan Tunev ,  Joseph Traina

    发明人： Ya Guo ,  Stefan Tunev ,  Joseph Traina

    IPC分类号： A61M25/09 ,  A61M25/10

    CPC分类号： A61B17/22 ,  A61B2017/22038 ,  A61B2017/22084 ,  A61B2017/22094 ,  A61B2017/308

    摘要： A method of recanalizing a chronic total occlusion (CTO) is disclosed. A catheter with a guidewire slidingly received therein is positioned proximally adjacent to the CTO. An occlusion weakening therapy effective to quickly soften and/or loosen the CTO is delivered to the CTO via the catheter. The occlusion weakening therapy includes at least one enzyme and a chelating agent which are selectively deliverable either together or separately depending on the type of material encountered by the guidewire. According to various methods, the enzyme(s) may be delivered if tissue is encountered, the chelating agent may be delivered if calcification is encountered, and both enzyme(s) and chelating agent(s) may be delivered if a fibrous cap is encountered. The distal end of the guidewire may be advanced into the CTO shortly after delivery of the occlusion weakening therapy and is manipulated through the CTO until the guidewire successfully crosses the CTO.

    摘要翻译： 公开了一种再通过慢性完全闭塞（CTO）的方法。 具有滑动地容纳在其中的导丝的导管位于CTO的近侧。 有效快速软化和/或松开CTO的闭塞减弱治疗通过导管输送到CTO。 闭塞减弱治疗包括至少一种酶和螯合剂，其可以一起或分开选择性递送，这取决于导丝所遇到的材料的类型。 根据各种方法，如果遇到组织，则可以递送酶，如果遇到钙化，螯合剂可能被递送，并且如果遇到纤维帽，则可以递送两种酶和螯合剂 。 在输送阻塞减弱治疗之后，引导线的远端可以推进到CTO中，并且通过CTO被操纵直到导丝成功地穿过CTO。